Medisys PLC (MDY) Providing innovative solutions to the rapidly growing point-of-care diagnostic and healthcare worker safety markets. For more than 35 years, companies in the Medisys group have been advancing healthcare through development, manufacture and distribution of revolutionary medical products. The Group's mission is to become a leading worldwide provider of diagnostic systems and medical safety products enabling rapid, cost effective, on-site delivery of healthcare solutions.
For more than three decades, Medisys' primary operating unit, Hypoguard, has been devoted to advancing personal and professional healthcare management. The Company's core focus is diabetes glucose self-monitoring - a rapidly growing market of nearly $5 billion worldwide.
'Medisys-group.com'
'Hypoguard.com'

15/02/2006
Medisys reported a 'considerable improvement' in trading during the first four months of its financial year, and said the business has been cash-flow neutral for the year to date.
The medical products company said competition in its core long-term care blood glucose monitoring business has not intensified. A drop in sales amid intense competition in the market caused a fall in sales and profits last year.
Sales volumes have recovered to previous highs by cutting prices and offering various promotions, Medisys reported this morning.
Margin improvements have been achieved faster than originally anticipated, it added. The company has benefited from cost saving measures implemented in the second half of the last financial year and cost reductions for its proprietary biosensor products.
Meanwhile, it has completed the development and manufacturing scale up of the first of the new systems it has designed for Menarini, the fifth largest worldwide branded marketer of blood glucose monitoring systems.
While the launch date is not yet clear, (Around March 1) Medisys predicted that sales of the products will be one of its key revenue growth drivers in the current financial year.


LATEST ON MDY V'S ROCHE COURT CASE
MDY V'S ROCHE COURT CASE Case IS Dismissed. http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread
My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

.

STIPULATION OF DISMISSAL WITH PREJUDICE
A settlement having been reached, the above-identified parties, through their
undersigned attorneys, hereby stipulate and agree pursuant to Fed. Rule Civ. P. 41 that the Plaintiffs Amended Complaint and the Defendants Amended Counterclaims in this case be dismissed with prejudice. The parties further stipulate that the Court shall retain jurisdiction over any disputes arising out of or related to the parties Confidential Settlement Agreement. Each of these parties will bear its own costs and attorneys fees.
Respectfully submitted,
s/Lynn C. Tyler
Donald E. Knebel
Larry A. Mackey
Lynn C. Tyler
Paul B. Hunt
Helen K. Geib
BARNES & THORNBURG LLP
11 South Meridian Street
Indianapolis, Indiana 46204
s/Robert W. Busby
Robert W. Busby
W. Jackson Matney, Jr.
Baker & McKenzie LLP
815 Connecticut Avenue, N.W.
Washington, DC 20006

It looks like its finely over. case be dismissed.

2/02/2006 21hrs
324
STIPULATION OF DISMISSAL WITH PREJUDICE
A settlement having been reached, the above-identified parties, through their
undersigned attorneys, hereby stipulate and agree pursuant to Fed. Rule Civ. P. 41 that the Plaintiffs Amended Complaint and the Defendants Amended Counterclaims in this case be dismissed with prejudice. The parties further stipulate that the Court shall retain jurisdiction over any disputes arising out of or related to the parties Confidential Settlement Agreement. Each of these parties will bear its own costs and attorneys fees.
Respectfully submitted,
s/Lynn C. Tyler
Donald E. Knebel
Larry A. Mackey
Lynn C. Tyler
Paul B. Hunt
Helen K. Geib
BARNES & THORNBURG LLP
11 South Meridian Street
Indianapolis, Indiana 46204
s/Robert W. Busby
Robert W. Busby
W. Jackson Matney, Jr.
Baker & McKenzie LLP
815 Connecticut Avenue, N.W.
Washington, DC 20006

325
This matter came before the Court upon the Stipulation of Dismissal of the plaintiffs,
Roche Diagnostics Corporation, Roche Diagnostics Operations, Inc., and Corange International,
Ltd. and the defendants, Apex Biotechnology Corporation, Hypoguard USA, Inc., and Medline
Industries, Inc. The Court, being duly advised, it is hereby
ORDERED that the Plaintiffs Amended Complaint and the Defendants Amended
Counterclaims are DISMISSED WITH PREJUDICE, with each party to bear its own costs and
attorneys fees.
IT IS FURTHER ORDERED THAT the Court shall retain jurisdiction over any
disputes arising out of or related to the parties Confidential Settlement Agreement.
SO ORDERED.

Too slow ! ;-)

moneyman
Well-done mm lets see what happens tomorrow.

Good luck 2u2

It looks like its finely over. case be dismissed.

2/02/2006 21hrs
LATEST ON MDY V'S ROCHE COURT CASE
http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread

The official version. The Court Case has finished.

For Immediate Release 3rd February 2006

Medisys PLC

('Medisys' or 'the Company')



Medisys announces that Hypoguard USA, Inc., the operator of the Company's US
blood glucose monitoring business, has in conjunction with the other parties to
the patent infringement complaint brought by Roche Diagnostics Corp. issued the
following agreed form announcement in relation to the settlement of the case:

Apex Biotechnology Corporation, Hypoguard USA, Incorporated, Medline Industries,
Inc. and Roche Diagnostics Corp. have agreed to a settlement favourable to all
parties for the patent infringement lawsuit pending in the United States
District Court Southern District of Indiana on January 31, 2006.

- Ends -

Recovery of the sp should now take place over the coming weeks with the court case out of the way.

From the last Results
CURRENT TRADING AND PROSPECTS
The current financial year is at an early stage, but to date trading has been in
line with expectations. Growth is expected to come primarily from the biosensor
based products, specifically through the alliance with Menarini and from the
introduction of the Assure Pro system into the LTC market. In addition the cost
savings realised in the latter part of 2005 will help to improve the financial
performance of the Group in the current year.

LONDON/ZURICH (Reuters) - Medisys said on Friday the operator of its U.S. blood glucose monitoring system had settled a patent row with Swiss drugmaker Roche, sending its shares over 14 percent higher.
At 10:15 a.m. Medisys (MDY.L: Quote, Profile, Research) shares were up 14.3 percent at 2.2 pence, valuing the firm at 11.9 million pounds.

Medisys said Hypoguard USA, the operator of its U.S. blood glucose monitoring business, and other parties, had settled a patent case brought by Roche in 2004.

"Apex Biotechnology Corporation, Hypoguard USA, Incorporated, Medline Industries, Inc. and Roche Diagnostics Corp. have agreed to a settlement favourable to all parties for the patent infringement lawsuit pending in the United States District Court Southern District of Indiana on January 31, 2006," Medisys said in a statement.

Analysts welcomed the deal, terms of which were not disclosed.

Michael King at Nomura Code Securities said the settlement dispelled fears that Medisys might have to pay royalties to Roche, which would have a negative impact on its earnings.

"This is clearly the final sorting out of it. It's a relief that the issue is no longer hanging over the stock," he said.

3m T trade sell that's what has held the price back all day.

not sure its a sell as in middle range could of been a average buy over the days trade ,would of thought a sell would of been 2 or below

biffa18
You may be right there heres hoping.

a lot more interest in MDY now-I'm hoping they start to climb soon.

moneyplus
Nice to here from you mp

Reposted,
Recovery of the sp should now take place over the coming weeks with the court case out of the way.

From the last Results
CURRENT TRADING AND PROSPECTS
The current financial year is at an early stage, but to date trading has been in
line with expectations. Growth is expected to come primarily from the biosensor
based products, specifically through the alliance with Menarini and from the
introduction of the Assure Pro system into the LTC market. In addition the cost
savings realised in the latter part of 2005 will help to improve the financial
performance of the Group in the current year.

Hi driver--still waiting for a flicker of life from PCM so no millions in that direction!!
so have added a few more MDY in hope of a bit of blue. Have you looked at OEP?
another long term one but I tucked away a few despite a comment from my brother that my coffin will be lined with long term share certificates!! no faith some people. cheers MP

The sp is bouncing about a bit today up 14% looking good after cc result.

A very nice 16.30% rise today, it's on the road to recovery.

Broken through the 3p 13% up recovering very nicely.

added a few more--building up my stake nicely!!